About Zentynel

Zentynel is Latin America’s first specialist biotech venture capital fund

Founded through the convergent vision of Fundación Ciencia & Vida and Venturance Alternative Assets, we combine capital, scientific depth, and operational expertise to help founders turn breakthrough science into scalable businesses.

 

With Fund I, we demonstrated the effectiveness of the model by investing in 17 companies in 6 countries and catalyzing more than US$100 million in co-investments.

 

With Fund II, we expand our reach: a US$ 50 million vehicle focused on Biotechnology and Healthtech, designed to bridge the region’s critical capital gap and create impact across human, animal, and environmental health.

Laboratory
Scientist Cells

Our Vision

Biotechnology is at the heart of the next industrial revolution, merging with AI, automation, and data to transform how we heal, feed, and sustain the planet. Latin America holds unique advantages, world-class scientific talent, unmatched biodiversity, cost-effective R&D, and growing entrepreneurial capacity.

 

Zentynel exists to unlock this potential, empowering founders with global ambition and helping the region move from promising to leading in biotech.

Our Strategy

We focus on early-stage ventures with global ambition and strong ties to Latin America. Our investments target:

  • Human and animal health: pharmaceuticals, vaccines, diagnostics, and medical devices.
  • Digital health and AI-driven platforms.
  • Agtech, foodtech, and environmental biotech solutions.

Our typical investment ranges from US$1–2 million, with 25–30% of the fund reserved for follow-ons. We are active investors, working alongside founders with hands-on operational support, international networks, and strategic guidance to accelerate growth and maximize impact.